Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted ...

But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

We came across a bullish thesis on Merck & Co., Inc. on Darius Dark Investing’s Substack. In this article, we will summarize ...

Merck & Co Inc. is seeking to raise as much as $8 billion through a corporate bond sale, with part of the proceeds expected ...

New Jersey’s pharma sector faces new layoffs as Merck cuts 204 jobs and Bristol Myers Squibb plans 110 reductions amid cost-saving efforts.

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report). The associated price target is $140.00. Charlie CY Yang has given his ...

Merck KGaA is an undervalued pharma company with a long history and strong fundamentals. The company has above-average margins and a diverse business portfolio in healthcare, life sciences, and ...

German science and technology company Merck KGaA has launched a supercomputer in Germany. Housed in an Equinix data center in ...

AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.